Novel Therapeutics from Modern Biotechnology

From Laboratory to Human Testing

  • Dale L. Oxender
  • Leonard E. Post
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 137)

Table of contents

  1. Front Matter
    Pages I-XVII
  2. A. S. Lubiniecki, J. C. Erickson, C. L. Nolan, R. G. Scott, P. J. Shadle, T. M. Smith et al.
    Pages 13-31
  3. C. R. Middaugh, R. Pearlman
    Pages 33-58
  4. M. L. Nucci, R. G. L. Shorr, A. Abuchowski
    Pages 59-88
  5. R. J. Kreitman, I. Pastan
    Pages 89-110
  6. T. G. Porter, S. G. Griego, T. K. Hart, D. E. Everitt, S. B. Dillon
    Pages 111-129
  7. A. A. Levin, S. P. Henry, C. F. Bennett, D. L. Cole, G. E. Hardee, G. S. Srivatsa
    Pages 131-163
  8. H. E. J. Hofland, L. Huang
    Pages 165-192
  9. H. Kotani, G. J. Mcgarrity
    Pages 193-219
  10. R. D. Armstrong, M. R. Koller, J. Maluta, W. C. Ogier
    Pages 221-241
  11. Back Matter
    Pages 243-248

About this book

Introduction

A cover story of Business Week Magazine in January 1984 stated "Biotech Comes of Age". In February 1986, Venture Magazine had a cover article entitled "The Biotech Revolution is Here". This article went on to say "New Genetic Technologies Will Transform Our Lives". These announcements were made many years after the first biotechnology companies, such as Genentech, Cetus, Amgen and Biogen, were formed-to commercialize the "New Biology". . At the time of writing this book, there are over 1300 biotech companies developing new technologies or identifying potential biotech drugs. Most of these companies were started in the height of the "high-technology hype", although companies are still forming as the technology advances. A more recent survey showed only a relatively small number of Food and Drug Administration (FDA) approvals among over several hundred biotech­ nology products now in clinical trial. One could ask why it has taken so long to produce biotechnology products. Part of the reason is that each new class of biotech products brings with it a set of problems that need to be solved before they enter clinical trials. These problems are often unique to biotechnology products, such as peptides, proteins, monoclonal antibodies, nucleic acids and cellular therapies.

Keywords

Downstream Processing Expression Nucleotide Tissue Engineering Vivo biotechnology chemistry chromatography gene expression gene therapy preparation protein proteins recombinant proteins tissue

Editors and affiliations

  • Dale L. Oxender
    • 1
  • Leonard E. Post
    • 1
  1. 1.Parke-Davis Pharmaceutical ResearchAnn ArborUSA

Bibliographic information

  • DOI https://doi.org/10.1007/978-3-642-59990-3
  • Copyright Information Springer-Verlag Berlin Heidelberg 1999
  • Publisher Name Springer, Berlin, Heidelberg
  • eBook Packages Springer Book Archive
  • Print ISBN 978-3-540-65927-3
  • Online ISBN 978-3-642-59990-3
  • Series Print ISSN 0171-2004
  • Series Online ISSN 1865-0325